Zobrazeno 1 - 10
of 1 134
pro vyhledávání: '"J. Roddick"'
Autor:
Alistair J. Roddick, Alexa Wonnacott, David Webb, Angela Watt, Michael A. Watson, Natalie Staplin, Alex Riding, Eirini Lioudaki, Apexa Kuverji, Mohsen El Kossi, Patrick Holmes, Matt Holloway, Donald Fraser, Chris Carvalho, James O. Burton, Sunil Bhandari, William G. Herrington, Andrew H. Frankel
Publikováno v:
BMC Nephrology, Vol 24, Iss 1, Pp 1-18 (2023)
Abstract Large placebo-controlled trials have demonstrated kidney and cardiovascular clinical benefits of SGLT-2 inhibitors. Data from the EMPA-KIDNEY and DELIVER trials and associated meta-analyses triggered an update to the UK Kidney Association Cl
Externí odkaz:
https://doaj.org/article/2551b161032e4b6e81d9951e0b305ac9
Publikováno v:
eJHaem, Vol 4, Iss 1, Pp 291-293 (2023)
Externí odkaz:
https://doaj.org/article/c53fadcaf8bc4ff883429902d0213e86
Autor:
Natalie Staplin, PhD, Alistair J. Roddick, MBBS, Jonathan Emberson, PhD, Christina Reith, FFPM, Alex Riding, PhD, Alexa Wonnacott, PhD, Apexa Kuverji, MBChB, Sunil Bhandari, PhD, Colin Baigent, FMedSci, Richard Haynes, DM, William G Herrington, FRCP
Publikováno v:
EClinicalMedicine, Vol 41, Iss , Pp 101163- (2021)
ABSTRACT: Background: The net absolute effects of sodium-glucose co-transporter-2 (SGLT-2) inhibitors across different patient groups have not been quantified. Methods: We performed a meta-analysis of published large (>500 participants/arm) placebo-c
Externí odkaz:
https://doaj.org/article/4983a729fe5e48f5bd3cacbcf535801e
Autor:
Angell, Alan
Publikováno v:
Bulletin of Latin American Research, 1984 Jan 01. 3(1), 162-163.
Externí odkaz:
https://www.jstor.org/stable/3338209
Autor:
Colin Baigent, JonathanR. Emberson, Richard Haynes, William G. Herrington, Parminder Judge, Martin J. Landray, Kaitlin J. Mayne, Sarah Y.A. Ng, David Preiss, Alistair J. Roddick, Natalie Staplin, Doreen Zhu, Stefan D. Anker, Deepak L. Bhatt, Martina Brueckmann, Javed Butler, David Z.I. Cherney, Jennifer B. Green, Sibylle J. Hauske, Hiddo J.L. Heerspink, Silvio E. Inzucchi, Meg J. Jardine, Chih-Chin Liu, Kenneth W. Mahaffey, Finnian R. McCausland, Darren K. McGuire, John J.V. McMurray, Bruce Neal, Brendon L. Neuen, Milton Packer, Vlado Perkovic, Marc S. Sabatine, Scott D. Solomon, Muthiah Vaduganathan, Christoph Wanner, David C. Wheeler, Stephen D. Wiviott, Faiez Zannad
Publikováno v:
The Lancet. 400:1788-1801
Large trials have shown that sodium glucose co-transporter-2 (SGLT2) inhibitors reduce the risk of adverse kidney and cardiovascular outcomes in patients with heart failure or chronic kidney disease, or with type 2 diabetes and high risk of atheroscl
Publikováno v:
eJHaem. 4:291-293
Autor:
A Kaura, A J Roddick, N A Samuel, A Mulla, B Glampson, J Davies, K Woods, R Kharbanda, R S Patel, A M Shah, D Perera, K M Channon, J Mayet
Publikováno v:
European Heart Journal. 43
Introduction Acute stroke accounts for significant morbidity and mortality globally. The role of troponin for risk stratification in stroke is unclear. Purpose The aims of this study were to assess the relationship between peak troponin and mortality
Autor:
A Kaura, N A Samuel, A J Roddick, B Glampson, A Mulla, J Davies, K Woods, R S Patel, A M Shah, D Perera, K M Channon, A S V Shah, J Mayet
Publikováno v:
European Heart Journal. 43
Background Cardiac troponin is commonly raised in patients with malignancy and may aid clinicians in risk prediction. The prognostic significance of raised troponin in these patients with known malignancies remains unclear. Purpose We sought to inves
Autor:
Alex M. Riding, Sunil Bhandari, William G. Herrington, Colin Baigent, Alistair J. Roddick, Natalie Staplin, Richard Haynes, Jonathan Emberson, Alexa Wonnacott, Apexa Kuverji, Christina Reith
Publikováno v:
EClinicalMedicine
EClinicalMedicine, Vol 41, Iss, Pp 101163-(2021)
EClinicalMedicine, Vol 41, Iss, Pp 101163-(2021)
Background The net absolute effects of sodium-glucose co-transporter-2 (SGLT-2) inhibitors across different patient groups have not been quantified. Methods We performed a meta-analysis of published large (>500 participants/arm) placebo-controlled SG
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::100287d9ce429791b47ac21a05784075
https://ora.ox.ac.uk/objects/uuid:92b557b0-3298-4b3c-9ac5-6e2e38f39e1b
https://ora.ox.ac.uk/objects/uuid:92b557b0-3298-4b3c-9ac5-6e2e38f39e1b
Autor:
Daniel Zehnder, Thomas Jaki, Katie Jeffery, Peter Horby, Tina George, Steven Scott, Lucy C Chappell, Richard Haynes, Maya H Buch, Kathryn M Rowan, Alan A Montgomery, Nigel E Brunskill, M Mafham, Tom Brown, David L. Roberts, George Koshy, Ni Ni Aung, Simon Tiberi, Jonathan Emberson, Guy E. Thwaites, Lise J Estcourt, Martin J Landray, Andrew D Mumford, Natalie Staplin, Leon Peto, Edmund Juszczak, Alistair J. Roddick, John Widdrington, Mark Campbell, Wei Shen Lim, Saul N. Faust, J Kenneth Baillie, Alison Uriel, Jeremy N. Day, Enti Spata, Guilherme Pessoa-Amorim
BackgroundTreatment of COVID-19 patients with plasma containing anti-SARS-CoV-2 antibodies may have a beneficial effect on clinical outcomes. We aimed to evaluate the safety and efficacy of convalescent plasma in patients admitted to hospital with CO
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::98e156731337cdb13e5b149ff83b3e6b
https://doi.org/10.1101/2021.03.09.21252736
https://doi.org/10.1101/2021.03.09.21252736